Our top pick for
Harvard Bioscience, Inc is a medical instruments & supplies business based in the US. Harvard Bioscience shares (HBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Harvard Bioscience employs 505 staff and has a trailing 12-month revenue of around USD$102.1 million.
|Latest market close||USD$4.1|
|52-week range||USD$1.39 - USD$4.58|
|50-day moving average||USD$4.0294|
|200-day moving average||USD$3.4618|
|Wall St. target price||USD$5.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.1239|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-6.39%|
|1 month (2020-12-17)||-2.38%|
|3 months (2020-10-16)||24.62%|
|6 months (2020-07-16)||19.53%|
|1 year (2020-01-16)||26.93%|
|2 years (2019-01-16)||19.53%|
|3 years (2018-01-16)||3.80%|
|5 years (2016-01-15)||50.74%|
Valuing Harvard Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harvard Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harvard Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 148x. In other words, Harvard Bioscience shares trade at around 148x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Harvard Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.89. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Harvard Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Harvard Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8.5 million.
The EBITDA is a measure of a Harvard Bioscience's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$102.1 million|
|Operating margin TTM||0.82%|
|Gross profit TTM||USD$64.6 million|
|Return on assets TTM||0.33%|
|Return on equity TTM||-8.62%|
|Market capitalisation||USD$159 million|
TTM: trailing 12 months
There are currently 584,383 Harvard Bioscience shares held short by investors – that's known as Harvard Bioscience's "short interest". This figure is 7.7% down from 632,869 last month.
There are a few different ways that this level of interest in shorting Harvard Bioscience shares can be evaluated.
Harvard Bioscience's "short interest ratio" (SIR) is the quantity of Harvard Bioscience shares currently shorted divided by the average quantity of Harvard Bioscience shares traded daily (recently around 110469.37618147). Harvard Bioscience's SIR currently stands at 5.29. In other words for every 100,000 Harvard Bioscience shares traded daily on the market, roughly 5290 shares are currently held short.
However Harvard Bioscience's short interest can also be evaluated against the total number of Harvard Bioscience shares, or, against the total number of tradable Harvard Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harvard Bioscience's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Harvard Bioscience shares in existence, roughly 20 shares are currently held short) or 0.0154% of the tradable shares (for every 100,000 tradable Harvard Bioscience shares, roughly 15 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Harvard Bioscience.
Find out more about how you can short Harvard Bioscience stock.
We're not expecting Harvard Bioscience to pay a dividend over the next 12 months.
Harvard Bioscience's shares were split on a 1319:1000 basis on 4 November 2013. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1319 shares. This wouldn't directly have changed the overall worth of your Harvard Bioscience shares – just the quantity. However, indirectly, the new 24.2% lower share price could have impacted the market appetite for Harvard Bioscience shares which in turn could have impacted Harvard Bioscience's share price.
Over the last 12 months, Harvard Bioscience's shares have ranged in value from as little as $1.39 up to $4.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harvard Bioscience's is 1.6945. This would suggest that Harvard Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems for use with custom amplifier configurations, vivo-systems solution for in vivo recordings with microelectrode arrays, and vitro-systems for extracellular recordings from microelectrode arrays in vitro; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.